Navigation Links
Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer
Date:2/2/2010

GERMANTOWN, Md., Feb. 2 /PRNewswire/ -- Sensors for Medicine and Science, Inc., a clinical-stage, medical device company pioneering breakthrough technology that could dramatically improve glucose monitoring for people with diabetes, today announced the appointment of Dr. Paul Strumph as the company's Chief Medical Officer.

Dr. Strumph was most recently Vice President and Chief Medical Officer of the Juvenile Diabetes Research Foundation.  At JDRF, his responsibilities included overseeing the clinical research portfolio and providing direction on clinical programs for JDRF's therapeutic areas, and providing guidance to JDRF on regulatory policy and therapeutic delivery issues, such as reimbursement and provider acceptance.  He was also a member of the four-person Research Senior Management Team that set Research Strategy, and validated Program Area strategies and execution.  

Prior to JDRF, Dr. Strumph held leadership positions in Clinical and Medical Affairs with Bristol-Myers Squibb & Co., Merck KGaA and GlaxoSmithKline, including clinical development of products in the therapeutic areas of diabetes, obesity and cardiovascular disease.  This experience included advancing therapeutic compounds through Phase I – IV clinical studies.  

Prior to entering industry, Dr. Strumph was a practicing endocrinologist and Clinical Assistant Professor at the UNC Department of Medicine.  He received his medical degree with distinction in research, from the University of Rochester School of Medicine and Dentistry and is a diplomate of boards in Internal Medicine, Endocrinology, Diabetes & Metabolism, Pediatrics, and Pediatric Endocrinology.

"I am delighted to join Sensors for Medicine and Science and contribute to the development of this groundbreaking technology," said Dr. Strumph.  "A long-term, continuous monitor that is sufficiently accurate to replace regular finger stick testing and does not require frequent calibration would be a major technical and clinical accomplishment.  Successful clinical development and commercialization of the Company's unique implanted glucose monitor could significantly improve the lives of people with diabetes."

"Paul is a great addition to our management team," said Marc Schneebaum, President & CEO of Sensors for Medicine and Science. "His distinguished reputation in the adult and pediatric diabetes communities and his extensive clinical and regulatory experience at all stages will be a perfect complement to our scientific team as we advance our long-term, implanted glucose monitor through clinical development and to commercialization. Moreover, his hands-on experience with glucose monitoring and insulin delivery technology should help us shape the product for optimal use by both people with diabetes and their physicians."

Sensors for Medicine and Science's lead product is a long-term, implanted continuous glucose monitor* based on its unique and proprietary sensor technology.  This product includes a miniaturized sensor and an external reader.  The sensor is inductively powered and remotely interrogated, so there is no battery on-board and no wires connecting the implanted sensor to the external reader.  As a result, after implantation, the sensor functions noninvasively, painlessly, automatically, and continuously.  Distinctive features include:

  • The sensor is designed to deliver accuracy that the Company believes could enable the product to replace regular finger stick monitoring.
  • The sensor is designed to deliver accurate results even when glucose levels are low, and when glucose levels are changing rapidly.  Accurate performance in these two situations is crucial to people with diabetes, and have proved to be particular challenges for competing devices.
  • The Company is targeting an implant period of up to one year, along with extended stability of calibration.

The Company plans to continue pilot clinical studies during 2010, and to initiate a pivotal clinical study in 2011.

About Sensors for Medicine and Science, Inc.

Sensors for Medicine and Science, Inc. is pioneering breakthrough technology that could dramatically improve glucose monitoring for people with diabetes.  The Company believes that its long-term, continuous glucose monitor technology has the potential to replace regular finger stick monitoring.  

Sensors for Medicine and Science, Inc. has also developed oxygen sensor technology, with potential applications in areas such as metabolic monitoring (weight management), respiratory and cardiac disease.  In addition, the Company sells its oxygen sensors as a component to original equipment manufacturers.

* NOTE: Sensors for Medicine and Science, Inc.'s glucose monitor is not available for sale and has not been approved by the U.S. Food and Drug Administration.

For more information about Sensors for Medicine and Science, Inc., please visit http://www.s4ms.com.

SOURCE Sensors for Medicine and Science, Inc.

RELATED LINKS
http://www.s4ms.com

'/>"/>

SOURCE Sensors for Medicine and Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
2. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
3. GSK Announces Open Innovation Strategy to Help Deliver New and Better Medicines for People Living in the Worlds Poorest Countries
4. European Medicines Agency (EMA) Waives Requirement to Test StemEx(R) in Paediatric Patients 17 Years of Age and Under
5. Medco Partners with AmeriCares to Rush Donated Medicines to Help Victims of the Haiti Earthquake
6. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
7. Asthmatx Pivotal Trial Manuscript for Bronchial Thermoplasty Published in the American Journal of Respiratory and Critical Care Medicine
8. Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine
9. World Renowned Physician and Thought Leader Dr. Eric J. Topol to Highlight Digital Medicine Revolution at International CES 2010
10. Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails
11. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , , Marks E-QURE , ... agreement, following similar agreements in Israel and ... 5 billion global market ... leader in medical devices for the treatment of advanced wound care, announced today ... in Colombia for the Company,s patented Bio-electrical Signal Therapy ...
(Date:1/19/2017)... Jan. 18, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... introducing the Aerolib Learning Management System: an On-demand E-learning system for Clinical ... and Hospital Administration that is based on Aerolib`s successful education methodology of ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... SF expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, ... growing demand of physicians and patients throughout the United States for high-quality human ...
(Date:1/19/2017)... ... 2017 , ... This month, the CEO and Clinical Director of Sober Living ... center in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO ... Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed ...
(Date:1/19/2017)... ... 19, 2017 , ... WhoHaha , a digital media company dedicated to ... (AHA) to produce a three-part video series that uses humor to highlight ways to ... launch of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans ...
(Date:1/19/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 with ... easier for their readers to get the information they desire. The procedures are now ... techniques used on those particular areas. , “We are excited to streamline our listings ...
Breaking Medicine News(10 mins):